Unlocking the Full Potential of RNAi with LEADTM (Ligand and Enhancer Assisted Delivery)
Time: 1:45 pm
day: Conference Day Two
Details:
- Ligand-mediated conjugate is often insufficient for extrahepatic delivery. Adding an enhancer addresses delivery inefficiencies including PK, receptor binding, internalization, or intracellular trafficking
- Sanegene’s innovative Ligand and Enhancer Assisted Delivery (LEAD™) technology has demonstrated robust siRNA delivery and potent gene knockdown across multiple extrahepatic tissues and cells, including muscle, adipose, macrophages, CNS/PNS, and ocular
- Leveraging LEAD™ technology to develop treatments for obesity and metabolic disorders by targeting the liver, muscle, and adipose tissues. LEAD™ technology demonstrates robust gene knockdown, weight loss, and improved body composition in combination with GLP-1RA or siRNA monotherapy
NEW DATA
